VU319

Phase I clinical trial of drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More